FDA approves Generic Copaxone – MNTA. MDCO thumbs up from Adcom. RPRX PDUFA date set + ALIOF CLSN EBIO PVCT STEM TRGT updates

Apr 16, 2015 No Comments by

Latest updates to the Company Pipeline Database for April 15 and 16. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALIOF 124.28 Ponesimod Relapsing multiple sclerosis Phase 3 Phase 3 initiated mid-April 2015 CLSN 2.94 ThermoDox Recurrent Chest Wall Breast Cancer (RCWBC) Phase 2 Phase 2 enrolment to be completed 3Q […]

Daily News Read more

Latest calendar updates for AEZS GALE NEOT

Apr 15, 2015 No Comments by

Latest updates to the Company Pipeline Database. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AEZS 0.58 Macimorelin Acetate – Macrilen Adult Growth Deficiency CRL CRL Nov 5 2014. Announced mid-April 2015 plans to initiate a Phase 3 trial GALE 1.45 NeuVax (E75) – PRESENT Cancer – low-to-intermediate HER2+ breast […]

Daily News Read more

SHPG PDUFA date set. EXEL data due 2H 2015. DERM initiates Phase 2 acne trial.

Apr 10, 2015 No Comments by

Latest updates to the Company Pipeline Database for April 9. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary DERM 15.15 DRM01 Acne Phase 2b Phase 2b initiated April 2015. Data due 1H 2016 EXEL 3.01 Cabozantinib – (METEOR) Cancer – metastatic renal cell cancer (RCC) Phase 3 Data due 2Q 2015 […]

Daily News Read more

ATHX data due April 19. HALO to initiate Phase 3 PEGPH20 in 1Q 2016 + updates for PTLA DSCO GLYC OCUL PFNX PVCT SRNE

Apr 09, 2015 No Comments

Latest updates to the Company Pipeline Database for April 6-8. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ATHX 3.12 Multistem Ischemic stroke Phase 2 Initiated 3Q 2011. Enrolment completed late Dec 2014. Initial data due April 19 2015 HALO 15.28 PEGPH20 Cancer – pancreatic Phase 2 Clinical hold lifted June […]

Read more

Updates for DYAX HRTX MDVN NDRM OCRX PRTK RPRX SAGE XENE XOMA

Apr 03, 2015 No Comments

Latest updates to the Company Pipeline Database for April 1 and 2. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary DYAX 27.05 DX-2930 Hereditary angioedema (HAE) Phase 2 Positive Phase 1b data released late March 2015. HRTX 14.07 APF530 – Sustol Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV) […]

Read more

TTNP data due 2Q. VRTX Adcom date set +updates for CAPR GWPH VTAE

Apr 01, 2015 No Comments

Latest updates to the Company Pipeline Database for March 31. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CAPR 8.70 Cenderitide Ambulatory heart failure Phase 2 Phase 2 enrolment completed late March 2015. Topline data due 2H 2015 GWPH 91.13 Epidiolex Dravet Syndrome Phase 2/3 Top line Phase 3 data expected […]

Read more

BDSI and CANF fail trials. AMGN granted priority review + ARGS update

Mar 31, 2015 No Comments

Latest updates to the Company Pipeline Database for March 30. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text AMGN 164.30 Kyprolis Relapsed multiple myeloma – patients who have received at least one prior therapy sNDA filing sNDA PDUFA priority review July 26, 2015 ARGS 9.52 AGS-003 ADAPT Trial mRCC Phase […]

Read more

Latest updates for ADMP ALDX CARA CNAT HTBX NEOT NERV OGXI OHRP ONTX OTIC PSDV ASND DERM EBS FWP LJPC LXRX RARE VBLT ZSAN

Mar 28, 2015 No Comments

Latest updates to the Company Pipeline Database for March 25-27. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ADMP 5.39 Epinephrine PFS Anaphylaxis CRL CRL issued March 27 2015 3/29/2015 ALDX 28.43 NS2 Noninfectious anterior uveitis Phase 2 Phase 2 initiated late March 2015. Preliminary due by end of […]

Read more

AERI Phase 3 data due mid 2Q 2015 + updates for ALDX LPCN LPTN MSTX

Mar 25, 2015 No Comments

Latest updates to the Company Pipeline Database for March 24. Refer to the FDA Calendar for upcoming catalysts: AERI 31.08 Rhopressa Glaucoma Phase 3 Phase 3 Rocket 1 trial data due mid-2Q 2015. Rocket 2 data due 3Q 2015 3/25/2015 ALDX 10.62 NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 3 initiated March 2015. Prelim data due by […]

Read more